Wall Street believes these three small companies have significant upside potential.
Is now a good time to buy these promising healthcare stocks?
The company announced preliminary trial results for its lead therapy.
Broader markets seemed likely to start out on a positive note despite these two outliers.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is engaged as a biotechnology company, which is focused on the research and development of
In a dour market open, here's why these stocks are on the rise.
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for...
WALTHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company...
WALTHAM, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. (“Viridian” or “the Company”)...